Carbohydrate mimotopes in the rational design of cancer vaccines

Current Topics in Medicinal Chemistry

Volumn 5, Issue 12, 2005, Pages 1171-1185

  Pashov, Anastas ^a   Perry, Marty ^b,c   Dyar, Michael ^b,c   Chow, Marie ^b   Kieber Emmons, Thomas ^a,b,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c OUACHITA BAPTIST UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARBOHYDRATE ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE RECEPTOR; GANGLIOSIDE GD2; LYMPHOCYTE ANTIGEN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; PEPTIDE LIBRARY; PLASMID DNA; RECOMBINANT ANTIGEN; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TUMOR ANTIGEN; VIRUS VECTOR;

BINDING SITE; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG TARGETING; GENE SEQUENCE; GENE STRUCTURE; GENE TARGETING; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNOLOGY; MELANOMA CELL; PHARMACOPHORE; REVIEW; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; T LYMPHOCYTE;

ADENOCARCINOMA; AMINO ACID SEQUENCE; CANCER VACCINES; CARBOHYDRATES; HUMANS; LEWIS BLOOD-GROUP SYSTEM; MODELS, MOLECULAR; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA;

EID: 27844597868     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802605774370928     Document Type: Review

References (140)

1. Steinman, R. M.; Mellman, I. Immunotherapy: bewitched, bothered, and bewildered no more. Science 2004, 305, 197-200.
2. Blattman, J. N.; Greenberg, P. D. Cancer immunotherapy: a treatment for the masses. Science 2004, 305, 200-205.
3. Mosolits, S.; Ullenhag, G.; Mellstedt, H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann. Oncol. 2005, 16, 847-862. Epub 2005 Apr 2013.
4. Mosolits, S.; Nilsson, B.; Mellstedt, H. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Rev. Vaccines 2005, 4, 329-350.
5. Galili, U. Autologous tumor vaccines processed to express alpha-gal epitopes: a practical approach to immunotherapy in cancer. Cancer Immunol. Immunother. 2004, 53, 935-945. Epub 2004 Jun 2016.
6. Murphy, A.; Westwood, J. A.; Teng, M. W.; Moeller, M.; Darcy, P. K. et al. Gene modification strategies to induce tumor immunity. Immunity 2005, 22, 403-414.
7. Lloyd, K. O. Carbohydrate vaccines for the immunotherapy of cancer. Drug News Perspect 2000, 13, 463-470.
8. Lazoura, E.; Apostolopoulos, V. Rational Peptide-based vaccine design for cancer immunotherapeutic applications. Curr. Med. Chem. 2005, 12, 629-639.
9. Bhattacharya-Chatterjee, M.; Chatterjee, S. K.; Foon, K. A. Antiidiotype antibody vaccine therapy for cancer. Expert Opin. Biol. Ther. 2002, 2, 869-881.
10. Chapman, P. B. Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. Curr. Opin. Investig. Drugs 2003, 4, 710-715.
11. Prud'homme, G. J. DNA vaccination against tumors. J. Gene Med. 2005, 7, 3-17.
12. Hussain, S. F.; Paterson, Y. What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors. Cancer Immunol. Immunother. 2005, 54, 577-586. Epub 2005 Jan 2014.
13. Markiewicz, M. A.; Kast, W. M. Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes. Cancer Invest. 2004, 22, 417-434.
14. Schultze, J. L.; Grabbe, S.; von Bergwelt-Baildon, M. S. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol. 2004, 25, 659-664.
15. Ikeda, H.; Chamoto, K.; Tsuji, T.; Suzuki, Y.; Wakita, D. et. al. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci. 2004, 95, 697-703.
16. Mapara, M. Y.; Sykes, M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J. Clin. Oncol. 2004, 22, 1136-1151.
17. Lollini, P. L.; Nicoletti, G.; Landuzzi, L.; De Giovanni, C.; Nanni, P. New target antigens for cancer immunoprevention. Curr. Cancer Drug Targets 2005, 5, 221-228.
18. Mocellin, S.; Rossi, C. R.; Nitti, D. Cancer vaccine development: on the way to break immune tolerance to malignant cells. Exp. Cell Res. 2004, 299, 267-278.
19. Sznol, M. Developing enabling technologies for the success of cancer immunotherapy. Curr. Opin. Investig. Drugs 2004, 5, 1239-1242.
20. Bonnefoy, J. Y. Cancer vaccines. Expert Opin. Ther. Targets 2004, 8, 521-525.
21. Monzavi-Karbassi, B.; Kieber-Emmons, T. Current concepts in cancer vaccine strategies. Biotechniques. 2001, 30, 170-172, 174, 176 passim.
22. Cunto-Amesty, G.; Monzavi-Karbassi, B.; Luo, P.; Jousheghany, F.; Kieber-Emmons, T. Strategies in cancer vaccines development. Int. J. Parasitol. 2003, 33, 597-613.
23. Mocellin, S.; Mandruzzato, S.; Bronte, V.; Lise, M.; Nitti, D. Part I: Vaccines for solid tumours. Lancet Oncol. 2004, 5, 681-689.
24. Yannelli, J. R.; Wroblewski, J. M. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine 2004, 23, 97-113.
25. Hakomori, S. Carbohydrate-to-carbohydrate interaction, through glycosynapse, as a basis of cell recognition and membrane organization. Glycoconj. J. 2004, 21, 125-137.
26. Hakomori, S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 2001, 491, 369-402.
27. Kyte, J. A.; Kvalheim, G.; Aamdal, S.; Saeboe-Larssen, S.; Gaudernack, G. Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination. Cancer Gene Ther. 2005, 12, 579-591.
28. Takahashi, T.; Johnson, T. D.; Nishinaka, Y.; Morton, D. L.; Irie, R. F. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J. Invest. Dermatol. 1999, 112, 205-209.
29. Zhang, H.; Zhang, S.; Cheung, N. K.; Ragupathi, G.; Livingston, P. O. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res. 1998, 58, 2844-2849.
30. Monzavi-Karbassi, B.; Artaud, C.; Jousheghany, F.; Hennings, L.; Carcel-Trullols, J. et al. Reduction of spontaneous metastases through induction of carbohydrate cross-reactive apoptotic antibodies. J. Immunol. 2005, 174, 7057-7065.
31. Ragupathi, G.; Liu, N. X.; Musselli, C.; Powell, S.; Lloyd, K. et al. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J. Immunol. 2005, 174, 5706-5712.
32. Vollmers, H. P.; Brandlein, S. The "early birds": natural IgM antibodies and immune surveillance. Histol. Histopathol. 2005, 20, 927-937.
33. McCool, T. L.; Harding, C. V.; Greenspan, N. S.; Schreiber, J. R. B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity. Infect Immun. 1999, 67, 4862-4869.
34. Gilewski, T.; Ragupathi, G.; Bhuta, S.; Williams, L. J.; Musselli, C. et al. Immunization of metastatic breast cancer patients with a filly synthetic globo H conjugate: a phase I trial. Proc. Natl. Acad. Sci. USA 2001, 98, 3270-3275.
35. Chapman, P. B.; Wu, D.; Ragupathi, G.; Lu, S.; Williams, L. et al. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin. Cancer Res. 2004, 10, 4717-4723.
36. Foon, K. A.; Lutzky, J.; Baral, R. N.; Yannelli, J. R.; Hutchins, L. et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J. Clin. Oncol. 2000, 18, 376-384.
37. Qiu, J.; Luo, P.; Wasmund, K.; Steplewski, Z.; Kieber-Emmons, T. Towards the development of peptide mimotopes of carbohydrate antigens as cancer vaccines. Hybridoma 1999, 18, 103-112.
38. Bolesta, E.; Kowalczyk, A.; Wierzbicki, A.; Rotkiewicz, P.; Bambach, B. et al. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer. Res. 2005, 65, 3410-3418.
39. Forster-Waldl, E.; Riemer, A. B.; Dehof, A. K.; Neumann, D.; Bramswig, K. et al. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. Mol. Immunol. 2005, 42, 319-325.
40. Willers, J.; Lucchese, A.; Kanduc, D.; Ferrone, S. Molecular mimicry of phage displayed peptides mimicking GD3 ganglioside. Peptides 1999, 20, 1021-1026.
41. O, I.; Kieber-Emmons, T.; Otvos, L. Jr.; Blaszczyk-Thurin, M. Peptides mimicking sialyl-Lewis A isolated from a random peptide library and peptide array. Ann. N. Y. Acad. Sci. 1999, 886, 276-279.
42. Kieber-Emmons, T.; Luo, P.; Qiu, J.; Chang, T. Y.; O, I. et al. Vaccination with carbohydrate peptide mimotopes promotes antitumor responses. Nat. Biotechnol. 1999, 17, 660-665.
43. Monzavi-Karbassi, B.; Luo, P.; Jousheghany, F.; Torres-Quinones, M.; Cunto-Amesty, G. et al. A mimic of tumor rejection antigen-associated carbohydrates mediates an antitumor cellular response. Cancer. Res. 2004, 64, 2162-2166.
44. Zuckier, L. S.; Berkowitz, E. Z.; Sattenberg, R. J.; Zhao, Q. H.; Deng, H. F. et al. Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model. Cancer Res. 2000, 60, 7008-7013.
45. Cunto-Amesty, G.; Luo, P.; Monzavi-Karbassi, B.; Lees, A.; Kieber-Emmons, T. Exploiting molecular mimicry to broaden the immune response to carbohydrate antigens for vaccine development. Vaccine 2001, 19, 2361-2368.
46. Monzavi-Karbassi, B.; Shamloo, S.; Kieber-Emmons, M.; Jousheghany, F.; Luo, P. et al. Priming characteristics of peptide mimotopes of carbohydrate antigens. Vaccine 2003, 21, 753-760.
47. Monzavi-Karbassi, B.; Cunto-Amesty, G.; Luo, P.; Shamloo, S.; Blaszcyk-Thurin, M. et al. Immunization with a carbohydrate mimicking peptide augments tumor-specific cellular responses. Int. Immunol. 2001, 13, 1361-1371.
48. Houghton, A. N.; Lloyd, K. O. Stuck in the MUC on the long and winding road. Nat. Med. 1998, 4, 270-271.
49. Meloen, R. H.; Puijk, W. C.; Slootstra, J. W. Mimotopes: realization of an unlikely concept. J. Mol. Recognit. 2000, 13, 352-359.
50. Partidos, C. D. Peptide mimotopes as candidate vaccines. Curr. Opin. Mol. Ther. 2000, 2, 74-79.
51. Monzavi-Karbassi, B.; Cunto-Amesty, G.; Luo, P.; Kieber-Emmons, T. Peptide mimotopes as surrogate antigens of carbohydrates in vaccine discovery. Trends Biotechnol. 2002, 20, 207-214.
52. Wang, L. F.; Yu, M. Epitope identification and discovery using phage display libraries: applications in vaccine development and diagnostics. Curr. Drug. Targets 2004, 5, 1-15.
53. Meng, W. S.; Butterfield, L. H. Rational design of peptide-based tumor vaccines. Pharm. Res. 2002, 19, 926-932.
54. Doytchinova, I. A.; Flower, D. R. Toward the quantitative prediction of T-cell epitopes: coMFA and coMSIA studies of peptides with affinity for the class I MHC molecule HLA-A*0201. J. Med. Chem. 2001, 44, 3572-3581.
55. Flower, D. R.; McSparron, H.; Blythe, M. J.; Zygouri, C.; Taylor, D. et al. Computational vaccinology: quantitative approaches. Novartis. Found Symp. 2003, 254, 102-120; discussion 120-105, 216-122, 250-102.
56. Zhihua, L.; Yuzhang, W.; Bo, Z.; Bing, N.; Li, W. Toward the quantitative prediction of T-cell epitopes: QSAR studies on peptides having affinity with the class I MHC molecular HLA-A*0201. J. Comput. Biol. 2004, 11, 683-694.
57. Borbulevych, O. Y.; Baxter, T. K.; Yu, Z.; Restifo, N. P.; Baker, B. M. Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J. Immunol. 2005, 174, 4812-4820.
58. Wang, B.; Sharma, A.; Maile, R.; Saad, M.; Collins, E. J. et al. Peptidic termini play a significant role in TCR recognition. J. Immunol. 2002, 169, 3137-3145.
59. Chen, J. L.; Stewart-Jones, G.; Bossi, G.; Lissin, N. M.; Wooldridge, L. et al. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J. Exp. Med. 2005, 201, 1243-1255.
60. Cabezas, E.; Wang, M.; Parren, P. W.; Stanfield, R. L.; Satterthwait, A. C. A structure-based approach to a synthetic vaccine for HIV-1. Biochemistry 2000, 39, 14377-14391.
61. Lerner, R. A. Tapping the immunological repertoire to produce antibodies of predetermined specificity. Nature 1982, 299, 593-596.
62. Green, N.; Alexander, H.; Olson, A.; Alexander, S.; Shinnick, T. M. et al. Immunogenic structure of the influenza virus hemagglutinin. Cell 1982, 28, 477-487.
63. Young, C. R.; Atassi, M. Z. Antibodies to sperm-whale myoglobin evoked by free synthetic peptides of an antigenic site. Immunol. Commun. 1982, 11, 9-16.
64. Lando, G.; Reichlin, M. Antigenic structure of sperm whale myoglobin. II. Characterization of antibodies preferentially reactive with peptides arising in response to immunization with the native protein. J. Immunol. 1982, 129, 212-216.
65. van Regenmortel, M. H. Molecular design versus empirical discovery in peptide-based vaccines. Coming to terms with fuzzy recognition sites and ill-defined structure-function relationships in immunology. Vaccine 1999, 18, 216-221.
66. Van Regenmortel, M. H. Antigenicity and immunogenicity of synthetic peptides. Biologicals 2001, 29, 209-213.
67. Lando, G.; Berzofsky, J. A.; Reichlin, M. Antigenic structure of sperm whale myoglobin. I. Partition of specificities between antibodies reactive with peptides and native protein. J. Immunol. 1982, 129, 206-211.
68. Hurrell, J. G.; Smith, J. A.; Leach, S. J. Immunological measurements of conformational motility in regions of the myoglobin molecule. Biochemistry 1977, 16, 175-185.
69. Timmerman, P.; Beld, J.; Puijk, W. C.; Meloen, R. H. Rapid and quantitative cyclization of multiple peptide loops onto synthetic scaffolds for structural mimicry of protein surfaces. Chembiochem. 2005, 6, 821-824.
70. Ferrat, G.; Renisio, J. G.; Morelli, X.; Slootstra, J.; Meloen, R. et al. A peptide mimic of an antigenic loop of alpha-human chorionic gonadotropin hormone: solution structure and interaction with a llama V(HH) domain. Biochem. J. 2002, 366, 415-422.
71. Dorow, D. S.; Shi, P. T.; Carbone, F. R.; Minasian, E.; Todd, P. E. et al. Two large immunogenic and antigenic myoglobin peptides and the effects of cyclisation. Mol. Immunol. 1985, 22, 1255-1264.
72. Paterson, Y. Delineation and conformational analysis of two synthetic peptide models of antigenic sites on rodent cytochrome c. Biochemistry 1985, 24, 1048-1055.
73. Irving, M. B.; Pan, O.; Scott, J. K. Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics. Curr. Opin. Chem. Biol. 2001, 5, 314-324.
74. Menendez, A.; Scott, J. K. The nature of target-unrelated peptides recovered in the screening of phage-displayed random peptide libraries with antibodies. Anal. Biochem. 2005, 336, 145-157.
75. Rowley, M. J.; O'Connor, K.; Wijeyewickrema, L. Phage display for epitope determination: A paradigm for identifying receptor-ligand interactions. Biotechnol. Annu. Rev. 2004, 10, 151-188.
76. Hafner, C.; Wagner, S.; Allwardt, D.; Riemer, A. B.; Scheiner, O. et al. Cross-reactivity of mimotopes with a monoclonal antibody against the high molecular weight melanoma-associated antigen (HMW-MAA) does not predict cross-reactive immunogenicity. Melanoma Res. 2005, 15, 111-117.
77. El Kasmi, K. C.; Deroo, S.; Theisen, D. M.; Brons, N. H.; Muller, C. P. Crossreactivity of mimotopes and peptide homologues of a sequential epitope with a monoclonal antibody does not predict crossreactive immunogenicity. Vaccine 1999, 18, 284-290.
78. Wagner, S.; Hafner, C.; Allwardt, D.; Jasinska, J.; Ferrone, S. et. al. Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J. Immunol. 2005, 174, 976-982.
79. Luo, W.; Hsu, J. C.; Tsao, C. Y.; Ko, E.; Wang, X. et al. Differential immunogenicity of two peptides isolated by high molecular weight-melanoma-associated antigen-specific monoclonal antibodies with different affinities. J. Immunol. 2005, 174, 7104-7110.
80. Ghiara, J. B.; Ferguson, D. C.; Satterthwait, A. C.; Dyson, H. J.; Wilson, I. A. Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site. J. Mol. Biol. 1997, 266, 31-39.
81. Villen, J.; Borras, E.; Schaaper; W. M.; Meloen, R. H.; Davila, M. et. al. Functional mimicry of a discontinuous antigenic site by a designed synthetic peptide. Chembiochem. 2002, 3, 175-182.
82. Kieber-Emmons, T.; Ward, R. E.; Raychaudhuri, S.; Rein, R.; Kohler, H. Rational design and application of idiotope vaccines. Int. Rev. Immunol. 1986, 1, 1-26.
83. Goodman, J. W. Modelling determinants for recognition by B cells and T cells. Chem. Immunol. 1989, 46, 1-22.
84. Koide, S.; Yang, X.; Huang, X.; Dunn, J. J.; Luft, B. J. Structure-based Design of a Second-generation Lyme Disease Vaccine Based on a C-terminal Fragment of Borrelia burgdorferi OspA. J. Mol. Biol. 2005, 350, 290-299.
85. Pizarro, J. C.; Vulliez-Le Normand, B.; Chesne-Seck, M. L.; Collins, C. R.; Withers-Martinez, C. et al. Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science. 2005, 308, 408-411. Epub 2005 Feb 2024.
86. Dakappagari, N. K.; Lute, K. D.; Rawale, S.; Steele, J. T.; Allen, S. D. et al. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. J. Biol. Chem. 2005, 280, 54-63. Epub 2004 Oct 2026.
87. Saarne, T.; Kaiser, L.; Gronlund, H.; Rasool, O.; Gafvelin, G. et al. Rational design of hypoallergens applied to the major cat allergen Fel d 1. Clin. Exp. Allergy. 2005, 35, 657-663.
88. Schreiber, A.; Humbert, M.; Benz, A.; Dietrich, U. 3D-Epitope-Explorer (3DEX): localization of conformational epitopes within three-dimensional structures of proteins. J. Comput. Chem. 2005, 26, 879-887.
89. Sundaram, R.; Lynch, M. P.; Rawale, S. V.; Sun, Y.; Kazanji, M. et al. De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies. J. Biol. Chem. 2004, 279, 24141-24151. Epub 22004 Apr 24141.
90. Melzer, H.; Baier, K.; Felici, F.; von Specht, B. U.; Wiedermann, G. et. al. Humoral immune response against proteophosphoglycan surface antigens of Entamoeba histolytica elicited by immunization with synthetic mimotope peptides. FEMS Immunol. Med. Microbiol. 2003, 37, 179-183.
91. Prinz, D. M.; Smithson, S. L.; Westerink, M. A. Two different methods result in the selection of peptides that induce a protective antibody response to Neisseria meningitidis serogroup C. J. Immunol. Methods 2004, 285, 1-14.
92. Maitta, R. W.; Datta, K.; Pirofski, L. A. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan. Vaccine 2004, 22, 4062-4068.
93. Park, I.; Choi, I. H.; Kim, S. J.; Shin, J. S. Peptide mimotopes of Neisseria meningitidis group B capsular polysaccharide. Yonsei Med. J. 2004, 45, 755-758.
94. Buchwald, U. K.; Lees, A.; Steinitz, M.; Pirofski, L. A. A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice. Infect. Immun. 2005, 73, 325-333.
95. Vyas, N. K.; Vyas, M. N.; Chervenak, M. C.; Bundle, D. R.; Pinto, B. M. et al. Structural basis of peptide-carbohydrate mimicry in an antibody-combining site. Proc. Natl. Acad. Sci. USA 2003, 100, 15023-15028. Epub 12003 Nov 15025.
96. Keitel, T.; Kramer, A.; Wessner, H.; Scholz, C.; Schneider-Mergener, J. et al. Crystallographic analysis of anti-p24 (HIV-1) monoclonal antibody cross-reactivity and polyspecificity. Cell 1997, 91, 811-820.
97. Luo, P.; Canziani, G.; Cunto-Amesty, G.; Kieber-Emmons, T. A molecular basis for functional peptide mimicry of a carbohydrate antigen. J. Biol. Chem. 2000, 275, 16146-16154.
98. Transue, T. R.; De Genst, E.; Ghahroudi, M. A.; Wyns, L.; Muyldermans, S. Camel single-domain antibody inhibits enzyme by mimicking carbohydrate substrate. Proteins 1998, 32, 515-522.
99. Bompard-Gilles, C.; Rousseau, P.; Rouge, P.; Payan, F. Substrate mimicry in the active center of a mammalian alpha-amylase: structural analysis of an enzyme-inhibitor complex. Structure 1996, 4, 1441-1452.
100. Cunto-Amesty, G.; Dam, T. K.; Luo, P.; Monzavi-Karbassi, B.; Brewer, C. F. et al. Directing the immune response to carbohydrate antigens. J. Biol. Chem. 2001, 276, 30490-30498. Epub 32001 May 30430.
101. Nair, D. T.; Singh, K.; Sahu, N.; Rao, K. V.; Salunke, D. M. Crystal structure of an antibody bound to an immunodominant peptide epitope: novel features in peptide-antibody recognition. J. Immunol. 2000, 165, 6949-6955.
102. Pozharski, E.; Moulin, A.; Hewagama, A.; Shanafelt, A. B.; Petsko, G. A. et al. Diversity in hapten recognition: structural study of an anti-cocaine antibody M82G2. J. Mol. Biol. 2005, 349, 570-582. Epub 2005 Apr 2021.
103. Berquand, A.; Xia, N.; Castner, D. G.; Clare, B. H.; Abbott, N. L. et al. Antigen binding forces of single antilysozyme Fv fragments explored by atomic force microscopy. Langmuir 2005, 21, 5517-5523.
104. Collis, A. V.; Brouwer, A. P.; Martin, A. C. Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. J. Mol. Biol. 2003, 325, 337-354.
105. Agadjanyan, M.; Luo, P.; Westerink, M. A.; Carey, L. A.; Hutchins, W. et al. Peptide mimicry of carbohydrate epitopes on human immunodeficiency virus. Nat. Biotechnol. 1997, 15, 547-551.
106. Hoffmuller, U.; Knaute, T.; Hahn, M.; Hohne, W.; Schneider-Mergener, J. et al. Evolutionary transition pathways for changing peptide ligand specificity and structure. EMBO J. 2000, 19, 4866-4874.
107. Pashov, A.; Canziani, G.; Macleod, S.; Plaxco, J.; Monzavi-Karbassi, B. et al. Targeting carbohydrate antigens in HIV vaccine development. Vaccine 2005, 23, 2168-2175.
108. Cunto-Amesty, G.; Luo, P.; Monzavi-Karbassi, B.; Lees, A.; Alexander, J. et al. Peptide mimotopes as prototypic templates of broad-spectrum surrogates of carbohydrate antigens. Cell Mol. Biol. (Noisy-le-grand) 2003, 49, 245-254.
109. Scott, J. K.; Loganathan, D.; Easley, R. B.; Gong, X.; Goldstein, I. J. A family of concanavalin A-binding peptides from a hexapeptide epitope library. Proc. Nat. Acad. Sci. USA 1992, 89, 5398-5402.
110. Oldenburg, K. R.; Loganathan, D.; Goldstein, I. J.; Schultz, P. G.; Gallop, M. A. Peptide ligands for a sugar-binding protein isolated from a random peptide library. Proc. Nat. Acad. Sci. USA 1992, 89, 5393-5397.
111. Hoess, R.; Brinkmann, U.; Handel, T.; Pastan, I. Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3. Gene 1993, 128, 43-49.
112. Oomen, C. J.; Hoogerhout, P.; Kuipers, B.; Vidarsson, G.; van Alphen, L. et al. Crystal Structure of an Anti-meningococcal Subtype P1.4 PorA Antibody Provides Basis for Peptide-Vaccine Design. J. Mol. Biol. 2005, 19, 19.
113. Cisar, J.; Kabat, E. A.; Domer, M. M.; Liao, J. Binding properties of immunoglobulin combining sites specific for terminal or nonterminal antigenic determinants in dextran. J. Exp. Med. 1975, 142, 435-459.
114. Padlan, E. A.; Kabat, E. A. Modeling of antibody combining sites. Methods Enzymol. 1991, 203, 3-21.
115. Bennett, L. G.; Glaudemans, C. P. The affinity of a linear, alpha-D-(1 leads to 6)-linked D-glucopyranan (dextran) for homogeneous immunoglobulin A W3129. Carbohydr. Res. 1979, 72, 315-319.
116. Nashed, E. M.; Perdomo, G. R.; Padlan, E. A.; Kovac, P.; Matsuda, T. et. al. Binding characteristics of IgA 16.4.12E, a monoclonal antibody with specificity for the nonreducing terminal epitope of alpha-(1----6)-dextrans. Comparisons between IgA hybridoma 16.4.12E and myeloma W3129. J. Biol. Chem. 1990, 265, 20699-20707.
117. Ziegler, T.; Sutoris, H.; Glaudemans, C. P. Binding studies on internal immunodeterminants: synthesis of beta-(1----6)-linked oligosaccharide methyl glycosides having one to four internal D-galactopyranosyl residues flanked by gentiobiose residues. Carbohydr. Res. 1992, 229, 271-291.
118. Villeneuve, S.; Souchon, H.; Riottot, M. M.; Mazie, J. C.; Lei, P. et. al. Crystal structure of an anti-carbohydrate antibody directed against Vibrio cholerae O1 in complex with antigen: molecular basis for serotype specificity. Proc. Natl. Acad. Sci. USA 2000, 97, 8433-8438.
119. Harris, S. L.; Craig, L.; Mehroke, J. S.; Rashed, M.; Zwick, M. B. et. al. Exploring the basis of peptide-carbohydrate crossreactivity: evidence for discrimination by peptides between closely related anti-carbohydrate antibodies. Proc. Natl. Acad. Sci. USA 1997, 94, 2454-2459.
120. Rodi, D. J.; Soares, A. S.; Makowski, L. Quantitative assessment of peptide sequence diversity in M13 combinatorial peptide phage display libraries. J. Mol. Biol. 2002, 322, 1039-1052.
121. Burritt, J. B.; Bond, C. W.; Doss, K. W.; Jesaitis, A. J. Filamentous phage display of oligopeptide libraries. [Review] [102 refs]. Analytical Biochemistry 1996, 238, 1-13.
122. Bailey, T. L.; Elkan, C. Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proc. Int. Conf. Intell. Syst. Mol. Biol. 1994, 2, 28-36.
123. Castano, A. R.; Tangri, S.; Miller, J. E.; Holcombe, H. R.; Jackson, M. R. et al. Peptide binding and presentation by mouse CD1 [see comments]. Science 1995, 269, 223-226.
124. Ishikawa, D.; Kikkawa, H.; Ogino, K.; Hirabayashi, Y.; Oku, N. et al. GD1alpha-replica peptides functionally mimic GD1alpha, an adhesion molecule of metastatic tumor cells, and suppress the tumor metastasis. FEBS Lett. 1998, 441, 20-24.
125. Rigoutsos, I.; Floratos, A. Combinatorial pattern discovery in biological sequences: The TEIRESIAS algorithm. Bioinformatics 1998, 14, 55-67.
126. Manivel, V.; Bayiroglu, F.; Siddiqui, Z.; Salunke, D. M.; Rao, K. V. S. The Primary Antibody Repertoire Represents a Linked Network of Degenerate Antigen Specificities. J. Immunol. 2002, 169, 888-897.
127. Tchernychev, B.; Cabilly, S.; Wilchek, M. The epitopes for natural polyreactive antibodies are rich in proline. Proc. Natl. Acad. Sci. USA 1997, 94, 6335-6339.
128. Kabat, E. A.; Wu, T. T. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J. Immunol. 1991, 147, 1709-1719.
129. Steplewski, Z.; Blaszczyk-Thurin, M.; Lubeck, M.; Loibner, H.; Scholz, D. et al. Oligosaccharide Y specific monoclonal antibody and its isotype switch variants. Hybridoma 1990, 9, 201-210.
130. Blaszczyk-Thurin, M.; Murali, R.; Westerink, M. A.; Steplewski, Z.; Co, M. S. et al. Molecular recognition of the Lewis Y antigen by monoclonal antibodies. Protein Eng. 1996, 9, 447-459.
131. Ramsland, P. A.; Farrugia, W.; Bradford, T. M.; Mark Hogarth, P.; Scott, A. M. Structural convergence of antibody binding of carbohydrate determinants in Lewis Y tumor antigens. J. Mol. Biol. 2004, 340, 809-818.
132. Ramsland, P. A.; Farrugia, W.; Yuriev, E.; Edmundson, A. B.; Sandrin, M. S. Evidence for structurally conserved recognition of the major carbohydrate xenoantigen by natural antibodies. Cell Mol. Biol. (Noisy-le-grand) 2003, 49, 307-317.
133. Luo, P.; Agadjanyan, M.; Qiu, J.; Westerink, M. A.; Steplewski, Z. et al. Antigenic and immunological mimicry of peptide mimotopes of Lewis carbohydrate antigens. Mol. Immunol. 1998, 35, 865-879.
134. Bohm, H. J. Towards the automatic design of synthetically accessible protein ligands: peptides, amides and peptidomimetics. J. Comput. Aided Mol. Des. 1996, 10, 265-272.
135. Pichla, S. L.; Murali, R.; Burnett, R. M. The crystal structure of a Fab fragment to the melanoma-associated GD2 ganglioside. J. Struct. Biol. 1997, 119, 6-16.
136. O, I.; Otvos, L.; Kieber-Emmons, T.; Blaszczyk-Thurin, M. Role of SA-Le(a) and E-selectin in metastasis assessed with peptide antagonist. Peptides 2002, 23, 999-1010.
137. Johnson, M. A.; Pinto, B. M. NMR spectroscopic and molecular modeling studies of protein-carbohydrate and protein-peptide interactions. Carbohydr. Res. 2004, 339, 907-928.
138. Wang, J. X.; Dipasquale, A. J.; Bray, A. M.; Maeji, N. J.; Spellmeyer, D. C. et al. Systematic study of substance P analogs. II. Rapid screening of 512 substance P stereoisomers for binding to NK1 receptor. Int. J. Pept. Protein. Res. 1993, 42, 392-399.
139. Moriyama, H.; Hiramatsu, Y.; Kiyoi, T.; Achiha, T.; Inoue, Y. et al. Studies on selectin blocker. 9. SARs of non-sugar selectin blocker against E-, P-, L-selectin bindings. Bioorg. Med. Chem. 2001, 9, 1479-1491.
140. Wang, X.; Niu, Y.; Cao, X.; Zhang, L.; Zhang, L. H. et al. 3D-QSAR analysis of sialyltransferase inhibitors. Bioorg. Med. Chem. 2003, 11, 4217-4224.